Harmony Biosciences’ Post

BRAIN Biotech AG, our parent company, released their annual report FY 2022/23. Read the highlights from the BRAIN Biotech Group's past fiscal year below https://lnkd.in/gkm9fQwP   #Biotechnology #AnnualReport #BRAINBiotechGroup

Click the link below to find out the details about our upcoming Year-End earnings results and associated conference call!

Learn more about INIA Bioscience's vision of making biologics obsolete in the treatment of psoriasis, providing patients with a superior, side-effect-free alternative. Watch the video here: https://lnkd.in/et3aqUBM

In SRI's Biosciences Division, we work to develop next-generation drugs, diagnostics, and technologies to solve urgent medical needs. We're a unique blend of academic and biotech environments with three focus areas — basic research, applied sciences, and translational development. “Because we’re a nonprofit with a mission to make the world a better place, there’s a lot of flexibility in the types of projects we can pursue. We can do earlier stage research that may have higher impact without as much emphasis on the bottom line. And when we collaborate with pharmaceutical companies, it’s truly a co-development process — sharing expertise and innovating together.” said division president Kathlynn Brown. Learn more about us: https://lnkd.in/ejPZDXVz #drugdevelopment #precisionmedicine #biomedical

Learn more about INIA Bioscience's vision of making biologics obsolete in the treatment of psoriasis, providing patients with a superior, side-effect-free alternative. Watch the video here: https://lnkd.in/ez7rqXv7

Earlier today, we shared a strategic update where we discussed progress towards our 2024 goals, including achievement of establishing in vivo preclinical proof of concept. Learn more: https://bit.ly/3YyS3GL #geneediting #biotechnology  

A nice recap of drug transformation in 2021 reflecting on the role of biotransformation in discovery & development phases and current trends of new modality biotransformation. Taylor & Francis Group #discoveryservices #bioanalysis

Exciting news from kashiv BioSciences! We announced the completion of Phase 3 patients recruitment for our first Mab molecule and have entered into a commercial partnership for the US, EU, and the rest of the world. Stay tuned for more updates on this groundbreaking development! #Biotechnology #Healthcare #Innovation

Thanks for all who attended the #BIO session "𝗘𝘅𝗽𝗹𝗼𝗿𝗶𝗻𝗴 𝘁𝗵𝗲 𝗙𝘂𝘁𝘂𝗿𝗲 𝗼𝗳 𝗚𝗲𝗻𝗲 𝗗𝗲𝗹𝗶𝘃𝗲𝗿𝘆" moderated by our own Ola Tuvesson...the turn out was great! For those who missed it, here are some key takeaways from the panel with Amy Walker, Johan Rockberg, Henk Johan Streefkerk, Jayesh Kulkarni: - One technology will not be fit for all purposes, we need a toolbox of different delivery technologies. - We have come a long way in developing #gene delivery methods but still there is a lot of potential for the next generation systems. - We need to address the manufacturing processes to get costs down and make #CGT's acceptable for the larger patient groups. This is best done by adapting a holistic approach, looking at everything from payload design to increased specificity and higher potency. Thanks all for making it a great success and looking forward to the next one. #LetsJourneyTogether #BIOUSA, #CellandGeneTherapy, #GeneDelivery, SwedenBIO, NorthX Biologics

At #BPIWEST? Be sure to attend these two incredible tech talks: Dr. Joshi's talk, "Scaling-up therapeutic bioproduction with CELLiST™ BASAL CHO MX Medium," will be held on Wednesday, March 13 at 11:00 AM PT. Learn how CELLiST™ BASAL CHO MX media (@JSR Life Sciences) enables us to scale up therapeutic bioproduction by supporting higher titers and improved cell growth. Come to Dr. Ryan's talk, "Applying a platform mAb Approach to Multi-Specifics," at 2:00 PM PT on Wednesday, March 13. Dive into how our platform approaches, and our integration of both process and analytical development, have enabled us to produce multispecifics on mAb timelines. #Biotech #Biopharma #Bioproduction #Processdevelopment